126 related articles for article (PubMed ID: 22995920)
1. Persistent complete response after single-agent sunitinib treatment in a case of TFE translocation positive relapsed metastatic pediatric renal cell carcinoma.
Chowdhury T; Prichard-Jones K; Sebire NJ; Bier N; Cherian A; Sullivan MO; O'Meara A; Anderson J
J Pediatr Hematol Oncol; 2013 Jan; 35(1):e1-3. PubMed ID: 22995920
[TBL] [Abstract][Full Text] [Related]
2. Sunitinib-induced nephrotic syndrome in association with drug response in a patient with Xp11.2 translocation renal cell carcinoma.
Liu YC; Chang PM; Liu CY; Yang CY; Chen MH; Pan CC; Chen MH
Jpn J Clin Oncol; 2011 Nov; 41(11):1277-81. PubMed ID: 21965162
[TBL] [Abstract][Full Text] [Related]
3. A case study of metastatic Xp11.2 translocation renal cell carcinoma effectively treated with sunitinib.
Numakura K; Tsuchiya N; Yuasa T; Saito M; Obara T; Tsuruta H; Narita S; Horikawa Y; Satoh S; Habuchi T
Int J Clin Oncol; 2011 Oct; 16(5):577-80. PubMed ID: 21161315
[TBL] [Abstract][Full Text] [Related]
4. Vascular endothelial growth factor-targeted therapy for the treatment of adult metastatic Xp11.2 translocation renal cell carcinoma.
Choueiri TK; Lim ZD; Hirsch MS; Tamboli P; Jonasch E; McDermott DF; Dal Cin P; Corn P; Vaishampayan U; Heng DY; Tannir NM
Cancer; 2010 Nov; 116(22):5219-25. PubMed ID: 20665500
[TBL] [Abstract][Full Text] [Related]
5. An adult Xp11.2 translocation renal carcinoma showing response to treatment with sunitinib.
Pwint TP; Macaulay V; Roberts IS; Sullivan M; Protheroe A
Urol Oncol; 2011; 29(6):821-4. PubMed ID: 19962921
[TBL] [Abstract][Full Text] [Related]
6. Translocation renal cell carcinoma: lack of negative impact due to lymph node spread.
Geller JI; Argani P; Adeniran A; Hampton E; De Marzo A; Hicks J; Collins MH
Cancer; 2008 Apr; 112(7):1607-16. PubMed ID: 18278810
[TBL] [Abstract][Full Text] [Related]
7. Intermittent treatment with sunitinib may achieve complete response in metastatic renal cell carcinoma.
Aksu G; Ensaroglu F; Dolasik I; Temiz S; Halis H; Sener SY; Kaya A; Uygun K
J BUON; 2010; 15(4):798-9. PubMed ID: 21229650
[No Abstract] [Full Text] [Related]
8. A case of adult metastatic Xp11 translocation renal cell carcinoma treated successfully with sunitinib.
Choueiri TK; Mosquera JM; Hirsch MS
Clin Genitourin Cancer; 2009 Oct; 7(3):E93-4. PubMed ID: 19815489
[TBL] [Abstract][Full Text] [Related]
9. Complete response to sunitinib in a patient with relapsed irresectable renal cell carcinoma.
Vaz MA; Pachón V; Grande E; Ferreiro R; Carrato A
Anticancer Drugs; 2011 Sep; 22(8):817-21. PubMed ID: 21566523
[TBL] [Abstract][Full Text] [Related]
10. [Clinicopathologic and molecular genetic study of renal cell carcinoma occurring in teenagers].
Rao Q; Zhou J; Zhang RS; Ma HH; Zhou HB; Lu ZF; Zhou XJ
Zhonghua Bing Li Xue Za Zhi; 2010 Sep; 39(9):582-6. PubMed ID: 21092583
[TBL] [Abstract][Full Text] [Related]
11. Prolonged complete responses and near-complete responses to sunitinib in metastatic renal cell carcinoma.
Heng DY; Rini BI; Garcia J; Wood L; Bukowski RM
Clin Genitourin Cancer; 2007 Dec; 5(7):446-51. PubMed ID: 18272027
[TBL] [Abstract][Full Text] [Related]
12. Xp11 translocation renal cell carcinoma in adults: expanded clinical, pathologic, and genetic spectrum.
Argani P; Olgac S; Tickoo SK; Goldfischer M; Moch H; Chan DY; Eble JN; Bonsib SM; Jimeno M; Lloreta J; Billis A; Hicks J; De Marzo AM; Reuter VE; Ladanyi M
Am J Surg Pathol; 2007 Aug; 31(8):1149-60. PubMed ID: 17667536
[TBL] [Abstract][Full Text] [Related]
13. [Efficacy of Sunitinib Rechallenge in Metastatic Renal Cell Carcinoma : A Case Report].
Yoshinaga A; Kamata S
Hinyokika Kiyo; 2015 May; 61(5):201-5. PubMed ID: 26087822
[TBL] [Abstract][Full Text] [Related]
14. Long-term response with sunitinib for metastatic renal cell carcinoma.
Ronnen EA; Kondagunta GV; Ginsberg MS; Russo P; Motzer RJ
Urology; 2006 Sep; 68(3):672.e19-20. PubMed ID: 16979716
[TBL] [Abstract][Full Text] [Related]
15. Altered transcription factor E3 expression in unclassified adult renal cell carcinoma indicates adverse pathological features and poor outcome.
Mir MC; Trilla E; de Torres IM; Panizo A; Zlotta AR; Van Rhijn B; Morote J
BJU Int; 2011 Jul; 108(2 Pt 2):E71-6. PubMed ID: 21070573
[TBL] [Abstract][Full Text] [Related]
16. Renal carcinoma with (6;11)(p21;q12) translocation: report of an adult case.
Ishihara A; Yamashita Y; Takamori H; Kuroda N
Pathol Int; 2011 Sep; 61(9):539-45. PubMed ID: 21884304
[TBL] [Abstract][Full Text] [Related]
17. Utilization of a TFE3 break-apart FISH assay in a renal tumor consultation service.
Green WM; Yonescu R; Morsberger L; Morris K; Netto GJ; Epstein JI; Illei PB; Allaf M; Ladanyi M; Griffin CA; Argani P
Am J Surg Pathol; 2013 Aug; 37(8):1150-63. PubMed ID: 23715164
[TBL] [Abstract][Full Text] [Related]
18. Complete cerebral response with sunitinib for metastatic renal cell carcinoma.
Medioni J; Cojocarasu O; Belcaceres JL; Halimi P; Oudard S
Ann Oncol; 2007 Jul; 18(7):1282-3. PubMed ID: 17675397
[No Abstract] [Full Text] [Related]
19. Very late recurrence of renal cell carcinoma experiencing long-term response to sunitinib: a case report.
Messina C; Di Meglio A; Nuzzo PV; Boccardo F; Ricci F
Tumori; 2015; 101(3):e79-81. PubMed ID: 26045116
[TBL] [Abstract][Full Text] [Related]
20. Successful sunitinib treatment of metastatic renal cell carcinoma in a patient with end stage renal disease on hemodialysis.
Park CY
Anticancer Drugs; 2009 Oct; 20(9):848-9. PubMed ID: 19644356
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
